MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

ABSTRACT:

Purpose

Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may constitute a molecular marker for targeted therapy. We examined a GEC cohort with follow-up and reported the clinical response of four additional patients with MET-amplified tumors to the small molecule inhibitor crizotinib as part of an expanded phase I cohort study.

Patients and methods

From 2007 to 2009, patients with GEC were genetically screened as a consecutive series of 489 tumors (stages 0, I, and II, 39%; III, 25%; IV, 36%; n = 222 esophageal, including n = 21 squamous carcinomas). MET, EGFR, and HER2 amplification status was assessed by using fluorescence in situ hybridization.

Results

Ten (2%) of 489 patients screened harbored MET amplification; 23 (4.7%) harbored EGFR ampl

SUBMITTER: Lennerz JK 

PROVIDER: S-EPMC3255989 | biostudies-literature | 2011 Dec

REPOSITORIES: biostudies-literature